Subscribe To

Price Alert Latest News Economic Calendar News

OGN / Don't Buy Viatris And Organon Just Because Of The Dividends

Viatris and Organon are what can currently be described as "deep value plays" in the pharmaceutical sector. They face largely similar challenges, but on closer inspection are quite different companies. While I have already reported on Viatris' ever-changing portfolio, in this article I will take a closer look at Organon's portfolio and highlight the differences in strategy. Read More

Demo Live Account See Partner Details

Content Topics

Don

Viatris

Organon

Just

Because

Dividends

Stock

OGN

Posted: Feb 13 2023, 09:27

Author Name: Seeking Alpha

OGN News

By Seeking Alpha
November 2, 2023

Organon & Co (OGN) Q3 2023 Earnings Call Transcript

Organon & Co (NYSE:OGN ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO M

By Seeking Alpha
October 4, 2023

Organon: The Federal Reserve Black Swan (Rating Upgrade)

The stock of junk-rated Organon & Co. has lost more than 40% since my first article, largely due to interest rates continuing to rise. I take a close

By Seeking Alpha
September 10, 2023

6% Yield And Significantly Undervalued: A Closer Look At Organon

Organon & Co. stock is down 30% year-to-date and 40% below its 52-week highs. OGN offers a dividend yield of 5.8%, making it an attractive option for

By Seeking Alpha
August 8, 2023

Organon & Co (OGN) Q2 2023 Earnings Call Transcript

Organon & Co (NYSE:OGN ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Mat

By Reuters
August 8, 2023

Organon results beat estimates on demand for women heath products, biosimilars

Organon & Co reported better-than-expected second-quarter results on Tuesday, helped by strong demand for its women's heath products and biosimilar dr

By CNBC Television
July 14, 2023

Final Trades: SLB, Organon, IQVIA & more

The "Halftime Report" traders give their top picks to watch for the second half.

By Market Watch
July 5, 2023

Organon and Samsung Bioepis launch Humira biosimilar Hadlima in the U.S.

Organon & Co. OGN, -1.15% and partner Samsung Bioepis Co. Ltd. said Wednesday they have launched their Humira biosimilar Hadlima in the U.S. The move

By Reuters
July 1, 2023

Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount

Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's blockbuster arthritis

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.